Subfertility in Women with Spondyloarthritis: Key Insights from Recent Study
Women with spondyloarthritis (SpA) frequently face challenges in conceiving, with certain factors like advanced age and usage of nonsteroidal anti-inflammatory drugs (NSAIDs) prior to conception significantly extending the time to pregnancy.
Study Overview
A recent prospective observational study spanning 63 French medical centers aimed to understand the pregnancy timeline and its influencing factors among 88 women with SpA desiring to conceive. The participants, with an average age of 31.6 years and a mean body mass index of 23.8, were monitored from 2015 to 2021.
- During the preconception period, these women received various treatments, including tumor necrosis factor inhibitors (69.3%), NSAIDs (26.1%), conventional synthetic disease-modifying antirheumatic drugs (13.6%), and glucocorticoids (9.1%).
- Their disease activity was well-controlled, with an average Bath Ankylosing Spondylitis Disease Activity Index score of 2.9 at the start of the study.
Key Findings
The study revealed that 63.6% of the women with SpA successfully conceived during the follow-up period, with a median time to pregnancy of 16.1 months. This timeframe was measured from the cessation of contraception to confirmation of pregnancy.
However, 45.4% of the women took longer than 12 months to conceive or did not become pregnant at all within the five-year study span.
Notably, women exposed to NSAIDs during the preconception phase experienced a much longer time to pregnancy—median of 31.6 months—compared to those who did not, a threefold difference (hazard ratio [HR], 3.01; P = .01).
Maternal age was also a critical factor. Results showed that for each additional year of age, the risk of a longer time to pregnancy increased by 22%, reflecting the challenges faced by older women with SpA in achieving conception (HR per year, 1.22; P undisclosed).
Implications for Clinical Practice
The findings emphasize the importance of preconception counseling for all women with SpA who wish to start a family. Doctors and healthcare providers need to consider and address potential barriers to conception.
Specifically, for women struggling to conceive, it is crucial to reduce or discontinue NSAID use. The study highlights how these medications may significantly impede the fertility timeline among SpA patients.
Study Limitations
The study had several limitations that should be considered. The sample size was relatively small, which hindered the ability to conduct detailed subgroup analyses for different SpA phenotypes.
Additionally, missing data, particularly regarding disease activity, may have reduced the study’s analytical power. The research also lacked information on the frequency and dosage of NSAIDs received by the women, which could have provided more nuanced insights.
Conclusion
This study underscores the multifaceted nature of fertility issues in women with spondyloarthritis, highlighting the need for tailored preconception care. By addressing factors such as age and medication use, healthcare providers can support women with SpA in their journey to parenthood.
Call to Action
We invite you to share your thoughts on this research. How do you believe these findings can impact the fertility care of women with spondyloarthritis? Share your comments below and subscribe to our newsletter for more updates and insights in reproductive health. Don’t forget to like and share on your social media platforms to spread awareness!
